@article{3123477,
    title = "Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer",
    author = "Tanyi, J.L. and Bobisse, S. and Ophir, E. and Tuyaerts, S. and Roberti, A. and Genolet, R. and Baumgartner, P. and Stevenson, B.J. and Iseli, C. and Dangaj, D. and Czerniecki, B. and Semilietof, A. and Racle, J. and Michel, A. and Xenarios, I. and Chiang, C. and Monos, D.S. and Torigian, D.A. and Nisenbaum, H.L. and Michielin, O. and June, C.H. and Levine, B.L. and Powel, D.J., Jr. and Gfeller, D. and Mick, R. and Dafni, U. and Zoete, V. and Harari, A. and Coukos, G. and Kandalaft, L.E.",
    journal = "Science Translational Medicine",
    year = "2018",
    volume = "10",
    number = "436",
    publisher = "American Association for the Advancement of Science",
    issn = "1946-6234, 1946-6242",
    doi = "10.1126/scitranslmed.aao5931",
    keywords = "autologous oxidized whole tumor cell lysate pulsed dendritic cell vaccine;  bevacizumab;  cyclophosphamide;  dendritic cell vaccine;  tumor antigen;  unclassified drug;  bevacizumab;  cancer vaccine;  cyclophosphamide;  tumor antigen, adult;  aged;  Article;  cancer growth;  cancer immunization;  cancer survival;  CD8+ T lymphocyte;  cellular immunity;  clinical article;  controlled clinical trial;  controlled study;  drug efficacy;  drug manufacture;  drug safety;  female;  human;  low drug dose;  monotherapy;  ovary carcinoma;  phase 1 clinical trial;  pilot study;  priority journal;  somatic mutation;  unspecified side effect;  cytotoxic T lymphocyte;  dendritic cell;  genetics;  immunology;  immunotherapy;  metabolism;  mutation;  ovary tumor;  procedures, Antigens, Neoplasm;  Bevacizumab;  Cancer Vaccines;  Cyclophosphamide;  Dendritic Cells;  Female;  Humans;  Immunotherapy;  Mutation;  Ovarian Neoplasms;  T-Lymphocytes, Cytotoxic",
    abstract = "We conducted a pilot clinical trial testing a personalized vaccine generated by autologous dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC), which was injected intranodally in platinum-treated, immunotherapy-naïve, recurrent ovarian cancer patients. OCDC was administered alone (cohort 1, n = 5), in combination with bevacizumab (cohort 2, n = 10), or bevacizumab plus low-dose intravenous cyclophosphamide (cohort 3, n = 10) until disease progression or vaccine exhaustion. A total of 392 vaccine doses were administered without serious adverse events. Vaccination induced T cell responses to autologous tumor antigen, which were associated with significantly prolonged survival. Vaccination also amplified T cell responses against mutated neoepitopes derived from nonsynonymous somatic tumor mutations, and this included priming of T cells against previously unrecognized neoepitopes, as well as novel T cell clones of markedly higher avidity against previously recognized neoepitopes. We conclude that the use of oxidized whole-tumor lysate DC vaccine is safe and effective in eliciting a broad antitumor immunity, including private neoantigens, and warrants further clinical testing. Copyright © 2018, American Association for the Advancement of Science."
}